Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157280 | 0.83 | L3MBTL1 (0.37) | L3MBTL1LMNAMTNR1ARAB9ASMN1; SMN2 | |
| SCHEMBL7157600 | 0.79 | KMT2A (0.38) | L3MBTL1LMNAPKMRAB9ASMN1; SMN2 | |
| SCHEMBL6539019 | 0.73 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7154099 | 0.71 | RAB9A (0.32) | RAB9ASMN1; SMN2 | |
| SCHEMBL7595434 | 0.69 | NOS3 (0.31) | — | |
| SCHEMBL6538429 | 0.69 | HTR2C (0.33) | L3MBTL1LMNAPKMMTNR1ARAB9A | |
| SCHEMBL7157260 | 0.67 | L3MBTL1 (0.35) | L3MBTL1LMNARAB9AKMT2AMEN1 | |
| SCHEMBL7151996 | 0.67 | CA12 (0.43) | L3MBTL1PKMRAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6538230 | 0.65 | CA12 (0.46) | L3MBTL1LMNAPKMSMN1; SMN2KMT2A | |
| SCHEMBL6539544 | 0.65 | CA12 (0.46) | L3MBTL1LMNAPKMSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534542-B2 | For alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity | ALLERGEN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020161051-A1 | (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161051-A1 | (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors | ADRA2B, ADRB2, ADRA2C | L3MBTL1 1728/4885LMNA 4475/4885PKM 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.